Summary: Some factors affecting results of digoxin determinations using one commercially available radioimmunoassay kit are described and discussed.
Introduction
above mentioned factors, we investigated the specificity of different batches of antiserum to digoxin, and to The radioimmunoassay of digoxin in serum and plasma digitoxin and spironolactone. Moreover, measurements in is now a fairly common laboratory procedure. The biological fluids during pregnancy revealed interferences method and its clinical relevance have been extensively ^^ & 8 batches of antiserum which also showed a reported in the literature (1) (2) (3) (4) , Since the report of y^ degree of cross reaction with these drugs. In the generation of a specific antibody by Butler (5) and addition, false digoxin radioimmunoassay results also the introduction of a radioimmunoassay procedure by resulted from the presence of ethanol or a plasma expandSmith (6) andJEvered (7)> a number of investigators have er j n ^ assa y tube, reported various factors affecting the results of this assay. Some of the most important factors are: quenching (8) , radioactive contamination of patient's Materials and Methods serum (9) , chemiluminescence of serum (10) , lack of specificity of the antibody used (11), low intrinsic Chemicals (12) , and effects of albumin on this complex (13) . digoxinj horse serum> buffe , ( p hos phate-a lbumine buffer pH 7.40), and albumin coated activated charcoal.
In pur laboratories the digoxin radioimmunoassay has Crystalline digitoxin (Ned. Ph. VII, Nogepha, Aikmaar, The now been in use for about four years. With regard to the Netherlands). Procedures Digoxin radioimmunoassay is performed according to the supplier's instructions, and with the modifications reported earlier from our laboratories (11). Solutions of digoxin, spironolactone, digitoxin, Haemaccel, Rheomacrodex and Macrodex are prepared in the buffer supplied with the test kit, and assayed in the presence of horse serum to compensate for differences in standards and samples. As a measure of the intrinsic association constant of the antigenantibody complex, the residual radioactivity after 30 minutes adsorption to activated charcoal is measured in the supernatant after centrifugation, and expressed in percentage of the activity after one minute adsorption. For extraction, 10 ml methylene chloride is added to a 2 ml . sample. After mixing thoroughly but gently for 15 minutes, the tubes are centrifuged, the upper layers removed, and 6 ml of the methylene chloride fraction evaporated to dryness. The residue is dissolved in 0.1 ml ethanol and made up to 1.0 ml with buffer. Beta counting is conducted in either the Tricarb Model 2425 (Packard) or in the Mark II (Nuclear Chicago Corp., Des Plaines, 111. 60018) liquid scintillation counter. Quench correction was made by the external standard ratio method. Plasma or serum samples from patients on digoxin were drawn at least six hours after the last dose. Pools of maternal-and cord blood-serum and of amniotic fluid were obtained at delivery from nine women, who were not taking any medication.
Results and Discussion
After we started to determine plasma digoxin routinely in 1971, we were confronted with several types of interference with this assay. 
Spironolactone
In some patients without clinical signs of digoxin intoxication high plasma digoxin concentrations, suggesting toxicity, were measured. Some of these patients were medicated with both digoxin and spiroriolactone.
So we studied another group of patients using spironolactone only. Apparent digoxin concentrations of 0.3-1.7 μg/l were found in seven patients receiving daily doses of spironolactone of either 100 or 150 mg (16) . In table la the apparent digoxin concentrations, measured with different antibody charges at fixed spironolactone concentrations added in vitro are presented. Figure 1 shows the response of two antibody charges to increasing concentrations of spironolactone. Using antibody of charge no. K3650, an increasing cross reaction with spironolactone was found, but no significant effect was observed when antibody K7200 was used. So it is clear that the interference by spironolactone depends on the antibody charge used.
From .the active metabolites of spironolactone we could study only the effect of caiirenoate. This showed no cross reaction, probably because of opening of the γ-lactone ring. (See fig. 2 ). Unfortunately canfenon, the other metabolite which has a γ-lactone ring, was not available. In an article of Ravel (18) negligible interference by spironolactone and prednisone is described. Unfortunate^· ly he did riot mention the lot numbers of the kits he used, as his results using the Corning and Kallestädt kit suggest an antibpdy^dependent interference.
Moreover the dose of spironolactone administrated to the patients of Zeegers (11) was twice that received by the patients of Ravel
Digitoxin
The manual of the digoxin radioimmunoassay kit states that this kit can also be used for the estimation of serum digitoxin: "digitoxin will crossreact in the assay with about l/10th of the activity of digoxin on a weight basis". The first kits we used gave satisfactory results for the assay of digitoxin. However, when new lots were delivered, the cross reaction of digitoxin was reduced to about l/20th, and even l/40th of the activity of digoxin. Because of this lack of sensitivity to digitoxin we had to reject the kit for the digitoxin assay. To illustrate the effect of the quality of the antibody Table 1 b presents the apparent digoxin concentration in a serum containing 20 /ig/1 digitoxin, measured with different charges of antibody. One can conclude that a varying degree of cross reaction is found with different antibody charges. Therefore, when both substances are administered to patients, no uniform correction factor for the interference of digitoxin in the radioimmunoassay of digoxin can be applied as suggested by Kuno-Sakai (14) . In the paper of Kubasik et al. (15), who compared five commercially available kits for the radioimmunoassay of digoxin, two different lot numbered kits of each supplier, showed only minor variations. In our study, the antibody of the low numbered lots shows much more cross reaction than the high numbered.
Pregnancy (maternal blood, amniotic fluid, and cord blood)
In an attempt to study the placental passage of digoxin we found apparently toxic digoxin concentrations up to 6.2 Mg/1 in amniotic fluid and cord blood during pregnancy in five women taking digoxin. Maternal serum digoxin concentrations were in the normal therapeutic range. None of the babies showed any sign of digitalis intoxication. The result of the assays suggested accumulation of digoxin in amniotic fluid and cord blood.
However, values for digoxin in maternal plasma ranged from 0.2 to 0.7 /zg/1 in nine pregnant patients receiving no digoxin. Corresponding values for digoxin in amniotic fluid and cord blood plasma ranged from 1.35 to 2.5 Mg/1 (see also Jambroes et al. (16)). This interference was also found to depend on the antibody charge used. For this study pooled samples of maternal and fetal plasma, and amniotic fluid from the same pregnant women, not on digitalis, were assayed for apparent digoxin activity. The results are presented in table Ic, showing again an antibody charge-dependent interference with the radioimmunoassay of digoxin.
A study on transplacental passage of digoxin, using a reliable antibody, will be published elsewhere. (17) who also studied the effect of variations in contact time to charcoal stated that the magnitude of this effect varies with the manufacturer. Our results however emphasize differences between antibody charges from one manufacturer.
Influence of the association constant of the antibody
Smith & Haber related a poor intrinsic association constant of the antibody-antigen complex with a lack of specificity of the antibody. From the results in Table  la -d, especially with antibody charges no. χ, Κ8184, and K9100, one can see that their conclusion does not hold for all batches; from the results with those that we studied, it can be concluded that cross reaction with one interfering substance is concomittant with interference by other crossreactants.
With reference to the problems described so far, we would like to quote Th. W. Smith & E. Haber in Pharmacological Reviews 1973 (page 224). "Unfortunately, commercial suppliers of radioimmunoassay material have in general supplied the purchaser with inadequate data characterizing the antibodies supplied. The responsibility for quality control therefore rests with the user. Minimum documentation of the suitability of a given antibody for radioimmunoassay use would require hapten inhibition studies to define specificity, and charcoal contact time studies to define the range of contact times which could be used without introducing an unacceptable degree of error". In this study we have followed these suggestions for radioimmunoassay kits obtained from one manufacturer. Differences between several commercially available digoxin radioimmunoassay kits are extensively reported in literature (15) .
Haemaccel*)
In a study on digoxin pharmacokinetics in patients during cardiopulmonary bypass we sometimes found very low or even apparently negative plasma digoxin concentrations (tab. 2). No corrections were made for background counts in these samples. As a control the pump priming was measured, which gave an apparently negative digoxin level. As no radioactive contamination could be detected all constituents of the pump priming were tested. From these, Haemaccel turned out to interfere negatively with the radioimmunoassay of digoxin. We decided to study this effect more comprehensively.
The "in vitro" influence of Haemaccel is illustrated in figure 3 , representing a normal calibration curve and a calibration curve with addition of Haemaccel to the standards at a concentration of 5 g/1. From figure 3 one may see that the curves a and b do not run parallel. This means that there is no constant effect of Haemaccel in the digoxin concentration range we studied. When antibody is omitted (i.e. the blank), more radioactivity is measured in the presence of Haemaccel than in its absence. Less [ 3 H]digoxin is adsorbed to charcoal, depending on the Haemaccel concentration. When blanks were measured at different known unlabelled digoxin concentrations, no decrease of this effect could be detected. In other words, the influence of Haemaccel on the binding of digoxin to charcoal is independent of the digoxin concentration. There are no signs of interference in beta counting caused by quenching or chemiluminescence. So the effect must be attributed to interference with the adsorption to charcoal and possibly also with the formation of the antibody-antigen complex.
Though a combined administration of digoxin and Haemaccel is very rare, under these circumstances the observed interference may give rise to a misleading interpretation of serum digoxin assay results, especially at high digoxin levels. At zero digoxin concentrations a decrease of 0.1 μg/l is found; at a known digoxin value of 3.0 μg/l, the measured value may be decreased by as much as 1.0 μg/l. This interference was not observed with two other plasma substitutes, Macrodex and Rheomacroeex. To avoid the problems caused by Haemaccel, digoxin can be extracted from the samples with methylene chloride; as illustrated in figure 3 , curves c and d, normal and Haemaccel-containing standards then give the same values* For a clearer presentation rio correction was made for the fact that the final volume of 1.0 ml for extractions really represents 1.2 ml of sample.
It should be noticed that this extraction is not a standard procedure in the digoxin radioimmunoassay, and that the presence of Haemaccel in serum is not s easily recognized as haemolysis, jaundice or radioactive contamination.
Provided that Haemaccel does not interfere with the antibody-antigen binding, the observed phenomenon should be a stimulus to use separation techniques in which the antibody-antigen complex is removed, for example, by imm n -precipitation or by solid phase antibody.
and without Haemaccel, we concluded that ethanol might have an effect on the assay (see curves a and c in Fig. 3 ). To study this influence we replaced the normal buffer with buffer containing a quantity of ethanol equivalent to or twice that used after extraction.
The result of this addition is presented in figure 4 . It is clear that ethanol causes a small positive error in the assay. Ten percent ethanol in a sample causes about 0.1-0.2 jug/1 increase in the observed digoxin concentration (p < 0.05).
In patients undergoing cardiopulmonary bypass low plasma digoxin concentrations are to be expected, since digoxin administration is usually discontinued 48 hours prior to surgery. The small positive effect of ethanol may therefore lead to errors of up to 100% in the observed tissue: plasma ratio of digoxin. Moreover this experiment shows that the standards for the assay should not contain ethanol. Variations in results between commercially available kits may be caused by differences in the solvent of the standards. From the differences between extracted and unextracted samples, mentioned above, at zero digoxin concentration 
